Balance Sheet Components (Tables)

6 Months Ended

Jun. 30, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Cash and cash equivalents consisted of the following (in thousands):

	June 30, 2017		December 31, 2016
Cash	$	205,018	$	79,239
Money market funds		85,259		94,543
Total cash and cash equivalents	$	290,277	$	173,782

Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments

All investments are classified as available-for-sale. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale investments by major investments type are summarized in the tables below (in thousands):

	June 30, 2017
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Corporate bonds	$	86,266	$	67	$	(28	)	$	86,305
Certificate of deposits		1,036		—		—			1,036
Bond and mutual funds		20,053		744		—			20,797
Equity investments		126		61		—			187
Total investments	$	107,481	$	872	$	(28	)	$	108,325

	December 31, 2016
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Corporate bonds	$	126,550	$	182	$	(49	)	$	126,683
Certificate of deposits		1,037		—		—			1,037
Bond and mutual funds		22,305		157		—			22,462
Equity investments		125		100		—			225
Total investments	$	150,017	$	439	$	(49	)	$	150,407

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2017		December 31, 2016
Preclinical and clinical trial accruals	$	28,795	$	29,550
Payroll and related accruals		10,673		14,232
Professional services		1,653		1,252
Other		7,413		5,880
Total accrued liabilities	$	48,534	$	50,914